EMERAS (all delay) study - description and results

Trial-Results center
Clinical trial results database		Feedback Home

This trial is included in the following systematic reviews and meta-analyses:

acute myocardial infarction - fibrinolysis - all type of patients

acute myocardial infarction - myocardial revascularization - all type of patients

Related trials

ZEST AMI (vs SES), 2009 - zotarolimus ES vs sirolimus ES

TRIANA, 2009 - primary ballon angioplasty vs tenecteplase

NORDISTEMI, 2009 - thrombolysis + angioplasty vs immediate thrombolysis

Juwana, 2009 - sirolimus ES vs paclitaxel ES

ZEST AMI (vs PES), 2009 - zotarolimus ES vs paclitaxel ES

PASEO, 2009 - drug ES vs bare-metal stent

CARESS, 2008 - thrombolysis + angioplasty vs immediate thrombolysis

HORIZONS-AMI Stent, 2008 - paclitaxel ES vs bare-metal stent

MISSION, 2008 - sirolimus ES vs bare-metal stent

DEDICATION, 2008 - drug ES vs bare-metal stent

Díaz de la Llera, 2007 - sirolimus ES vs bare-metal stent

SESAMI, 2007 - sirolimus ES vs bare-metal stent

TYPHOON, 2006 - sirolimus ES vs bare-metal stent

PROSIT, 2006 - sirolimus ES vs paclitaxel ES

HAAMU-STENT, 2006 - paclitaxel ES vs bare-metal stent

PASSION, 2006 - paclitaxel ES vs bare-metal stent

WEST, 2006 - systematic PCI (+stent) vs no systematic PCI

CAPITAL AMI, 2005 - thrombolysis + angioplasty vs immediate thrombolysis

Di Lorenzo et al., 2005 - sirolimus ES vs paclitaxel ES

ZWOLLE 6, 2005 - primary stenting vs ballon angioplasty

CAPITAL AMI, 2005 - systematic PCI (+stent) vs no systematic PCI

senior PAMI, 2005 - primary PCI vs thrombolytic therapy

STOPAMI 3, 2004 - primary stenting vs ballon angioplasty

GRACIA-1, 2004 - systematic PCI (+stent) vs no systematic PCI

MERLIN (Sutton), 2004 - immediate systematic ballon angioplastyte vs no immediate angioplasty

See also:

All acute myocardial infarction clinical trials

All clinical trials of myocardial revascularization

All clinical trials of streptokinase

EMERAS (all delay) study, 1993

Treatments

Studied treatment	streptokinase 1.5 MU
Control treatment	placebo

Patients

Patients

patients entering hospital up to 24 h after the onset of suspected acute myocardial infarction

Method and design

Randomized effectives	2257 / 2277 (studied vs. control)
Design	Parallel groups
Blinding	double blind
Geographic area	south america

Results

Endpoint Studied treat.
n/N Control treat.
n/N Graph RR [95% CI]

short term death

269 / 2257
282 / 2277
0,96 [0,82;1,13] 0 2 1.0

Endpoint	Events (%)		Relative Risk	95% CI	Endpoint definition in the trial	Ref
Relative risks
Endpoint	Studied treat.	Control treat.	Relative Risk	95% CI	Endpoint definition in the trial	Ref
short term death	269 / 2257 (11,9%)	282 / 2277 (12,4%)	0,96	[0,82;1,13]	in hospital
The primary endpoint (if exists) appears in blod characters
Reference(s) used for data extraction: 0:

Endpoint	Events rate		Absolute risk reduction (ARR)
Absolute risk reduction
Endpoint	Studied treat.	Control treat.	Absolute risk reduction (ARR)
short term death	11,92%	12,38%	-4,7‰

Reference(s)

Trials register #

NA

. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. EMERAS (Estudio Multicéntrico Estreptoquinasa Repúblicas de América del Sur) Collaborative Group.. Lancet 1993;342:767-72
Pubmed | Hubmed | Fulltext

(c) 2004-2010 TrialResults-center - All Rights Reserved

Tweet this | notify a friend